Impact of COVID-19 pandemic on people with mental illness
Suggested citation:
Solov'eva KP, Morozova IO, Savenkova VI, et al. [Impact of COVID-19 pandemic on people with mental illness]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2023;(2):86-100. Russian
In this scientific review, in order to identify the features of the impact of the COVID-19 pandemic on patients with mental disorders, an attempt was made to summarize the data of the studies available to date. 75 articles were selected describing lifestyle changes in patients with mental disorders during the pandemic, the course of a new coronavirus infection in this cohort of patients, emerging mental and somatic complications, difficulties in choosing therapy, its side effects against a viral disease, problems of interaction between psychopharmacotherapy and antiviral drugs. The results obtained indicate a significant impact of coronavirus infection on patients with mental illness, confirm the need to take into account the COVID-19 factor when building a plan for diagnostic, therapeutic and rehabilitation measures.
Keywords COVID-19; psychiatry; neuropsychiatry; mental disorders
1. Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. DOI: https://doi.org/10.1208/s12248-020-00532-2 2. World Health Organization. Novel coronavirus (2019-nCoV): situation report, 1. Geneva: World Health Organization; 2020. URL: https://apps.who.int/iris/handle/10665/330760 (accessed on: 03.04.2023). 3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44. DOI: https://doi.org/10.1038/s41564-020-0695-z 4. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013;68(2):171–6. DOI: https://doi.org/10.1136/thoraxjnl-2012-202480 5. Mohan M, Perry BI, Saravanan P, Singh SP. COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis. Front Psychiatry. 2021;12:666067. DOI: https://doi.org/10.3389/fpsyt.2021.666067 6. Sartorious N. Comorbidity of mental and physical diseases: a main challenge for medicine of the 21st century. Shanghai Arch Psychiatry. 2013;25(2):68–9. DOI: https://doi.org/10.3969/j.issn.1002-0829.2013.02.002 7. Yazıcı S, Ahi ES, İlhan RS, Saka MC. The effect of the COVID-19 pandemic on health behavior and psychopathology in patients with psychotic disorders. Psychiatry Res. 2022;317:114845. DOI: https://doi.org/10.1016/j.psychres.2022.114845 8. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. DOI: https://doi.org/10.1016/S2215-0366(20)30090-0 9. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. DOI: https://doi.org/10.1016/S0140-6736(21)02143-7 10. Song H, Fall K, Fang F, et al. Stress related disorders and subsequent risk of life threatening infections: population based sibling controlled cohort study. BMJ. 2019;367:l5784. DOI: https://doi.org/10.1136/bmj.l5784 11. Pedersen A, Zachariae R, Bovbjerg DH. Influence of psychological stress on upper respiratory infection – a meta-analysis of prospective studies. Psychosom Med. 2010;72(8):823–32. DOI: https://doi.org/10.1097/PSY.0b013e3181f1d003 12. Severance EG, Dickerson FB, Viscidi RP, et al. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull. 2011;37(1):101–7. DOI: https://doi.org/10.1093/schbul/sbp052 13. Cipriani G, Danti S, Nuti A, et al. A complication of coronavirus disease 2019: delirium. Acta Neurol Belg. 2020;120(4):927–32. DOI: https://doi.org/10.1007/s13760-020-01401-7 14. Wang H, Lu J, Zhao X, et al. Alzheimer's disease in elderly COVID-19 patients: potential mechanisms and preventive measures. Neurol Sci. 2021;42(12):4913–20. DOI: https://doi.org/10.1007/s10072-021-05616-1 15. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124–30. DOI: https://doi.org/10.1002/wps.20806 16. Lee SW, Yang JM, Moon SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7(12):1025–31. DOI: https://doi.org/10.1016/S2215-0366(20)30421-1 17. Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophr Bull. 2020;46(4):752–7. DOI: https://doi.org/10.1093/schbul/sbaa051 18. Chen F, Chen Y, Wang Y, et al. The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms. Transl Neurodegener. 2022;11(1):40. DOI: https://doi.org/10.1186/s40035-022-00316-y 19. Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Mol Neurobiol. 2021;58(3):1017–23. DOI: https://doi.org/10.1007/s12035-020-02177-w 20. Xia X, Wang Y, Zheng J. COVID-19 and Alzheimer's disease: how one crisis worsens the other. Transl Neurodegener. 2021;10(1):15. DOI: https://doi.org/10.1186/s40035-021-00237-2 21. Courtenay K, Perera B. COVID-19 and people with intellectual disability: impacts of a pandemic. Ir J Psychol Med. 2020;37(3):231–6. DOI: https://doi.org/10.1017/ipm.2020.45 22. O'Leary L, Hughes-McCormack L, Dunn K, Cooper SA. Early death and causes of death of people with Down syndrome: A systematic review. J Appl Res Intellect Disabil. 2018;31(5):687–708. DOI: https://doi.org/10.1111/jar.12446 23. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100–6. DOI: https://doi.org/10.1016/j.bbi.2020.04.069 24. Favreau M, Hillert A, Osen B, et al. Psychological consequences and differential impact of the COVID-19 pandemic in patients with mental disorders. Psychiatry Res. 2021;302:114045. DOI: https://doi.org/10.1016/j.psychres.2021.114045 25. Palomar-Ciria N, Blanco Del Valle P, Hernández-Las Heras MÁ, Martínez-Gallardo R. Schizophrenia and COVID-19 delirium. Psychiatry Res. 2020;290:113137. DOI: https://doi.org/10.1016/j.psychres.2020.113137 26. Barlati S, Nibbio G, Vita A. Schizophrenia during the COVID-19 pandemic. Curr Opin Psychiatry. 2021;34(3):203–10. DOI: https://doi.org/10.1097/YCO.0000000000000702 27. Ma J, Hua T, Zeng K, et al. Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study. Transl Psychiatry. 2020;10(1):411. DOI: https://doi.org/10.1038/s41398-020-01098-5 28. Llach CD, Vieta E. Mind long COVID: Psychiatric sequelae of SARS-CoV-2 infection. Eur Neuropsychopharmacol. 2021;49:119–21. DOI: https://doi.org/10.1016/j.euroneuro.2021.04.019 29. McLoughlin J, O'Grady MM, Hallahan B. Impact of the COVID-19 pandemic on patients with pre-existing mood disorders. Ir J Psychol Med. 2021;39(4);363–72. DOI: https://doi.org/10.1017/ipm.2021.38 30. Diaz AD, Baweja R. The role of neurotropism in psychiatric patients with COVID-19. Eur Arch Psychiatry Clin Neurosci. 2021;271(2):385–6. DOI: https://doi.org/10.1007/s00406-020-01197-w 31. Moni MA, Lin PI, Quinn J, Eapen V. COVID-19 patient transcriptomic and genomic profiling reveals comorbidity interactions with psychiatric disorders. Transl Psychiatry. 2021;11(1):160. DOI: https://doi.org/10.1038/s41398-020-01151-3 32. Toubasi AA, AbuAnzeh RB, Tawileh H, et al. A meta-analysis: The mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res. 2021;299:113856. DOI: https://doi.org/10.1016/j.psychres.2021.113856 33. Tzur Bitan D, Krieger I, Kridin K, et al. COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study. Schizophr Bull. 2021;47(5):1211–7. DOI: https://doi.org/10.1093/schbul/sbab012 34. Fond G, Pauly V, Orleans V, et al. Increased in-hospital mortality from COVID-19 in patients with schizophrenia. Encephale. 2021;47(2):89–95. DOI: https://doi.org/10.1016/j.encep.2020.07.003 35. Nemani K, Li C, Olfson M, et al. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. JAMA Psychiatry. 2021;78(4):380–6. DOI: https://doi.org/10.1001/jamapsychiatry.2020.4442 36. Fond G, Pauly V, Leone M, et al. Mortality among inpatients with bipolar disorders and COVID-19: a propensity score matching analysis in a national French cohort study. Psychol Med. 2023;53(5):1979–88. DOI: https://doi.org/10.1017/S0033291721003676 37. Karaoulanis SE, Christodoulou NG. Do patients with schizophrenia have higher infection and mortality rates due to COVID-19? A systematic review. Psychiatriki. 2021;32(3):219–23. DOI: https://doi.org/10.22365/jpsych.2021.027 38. Courtenay K, Cooper V. Covid 19: People with learning disabilities are highly vulnerable. BMJ. 2021;374:n1701. DOI: https://doi.org/10.1136/bmj.n1701 39. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(11):1208–17. DOI: https://doi.org/10.1001/jamapsychiatry.2021.2274 40. Fornaro M, De Prisco M, Billeci M, et al. Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. J Affect Disord. 2021;295:740–51. DOI: https://doi.org/10.1016/j.jad.2021.08.091 41. Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med. 2020;382(18):1721–31. DOI: https://doi.org/10.1056/NEJMoa1915784 42. Yong N, Pan J, Li X, et al. Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study. Eur J Med Res. 2022;27(1):90. DOI: https://doi.org/10.1186/s40001-022-00706-y 43. Liang J, Cai Y, Xue X, et al. Does Schizophrenia Itself Cause Obesity? Front Psychiatry. 2022;13:934384. DOI: https://doi.org/10.3389/fpsyt.2022.934384 44. Perry C, Guillory TS, Dilks SS. Obesity and Psychiatric Disorders. Nurs Clin North Am. 2021;56(4):553–63. DOI: https://doi.org/10.1016/j.cnur.2021.07.010 45. Morais AHA, Passos TS, de Lima Vale SH, et al. Obesity and the increased risk for COVID-19: mechanisms and nutritional management. Nutr Res Rev. 2021;34(2):209–21. DOI: https://doi.org/10.1017/S095442242000027X 46. Zhand N, Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review. BJPsych Open. 2021;7(1):e35. DOI: https://doi.org/10.1192/bjo.2020.157 47. Mongan D, Cannon M, Cotter DR. COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders. Brain Behav Immun. 2020;88:9–10. DOI: https://doi.org/10.1016/j.bbi.2020.05.067 48. Nguyen TT, Dev SI, Chen G, et al. Abnormal levels of vascular endothelial biomarkers in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2018;268(8):849–60. DOI: https://doi.org/10.1007/s00406-017-0842-6 49. Gordon MN, Heneka MT, Le Page LM, et al. Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research. Alzheimers Dement. 2022;18(5):1038–46. DOI: https://doi.org/10.1002/alz.12488 50. Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2018;16(8):1210–23. DOI: https://doi.org/10.2174/1570159X15666170630163616 51. Garcia-Ribera C, Carrasco M, Ruiz-Ripoll A. Covid-19, hypercoagulability and risk of mortality in schizophrenia. Actas Esp Psiquiatr. 2021;49(4):194–5. PMID: 34195973 52. Ruan CJ, Zang YN, Cheng YH, et al. Around 3% of 1,300 Levels Were Elevated during Infections in a Retrospective Review of 131 Beijing Hospital In-Patients with More than 24,000 Days of Clozapine Treatment. Psychother Psychosom. 2020;89(4):255–7. DOI: https://doi.org/10.1159/000506355 53. Tio N, Schulte PFJ, Martens HJM. Clozapine Intoxication in COVID-19. Am J Psychiatry. 2021;178(2):123–7. DOI: https://doi.org/10.1176/appi.ajp.2020.20071039 54. Anmella G, Arbelo N, Fico G, et al. COVID-19 inpatients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry. J Affect Disord. 2020;274:1062–7. DOI: https://doi.org/10.1016/j.jad.2020.05.149 55. Plasencia-García BO, Rico-Rangel MI, Rodríguez-Menéndez G, et al. Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. Pharmacopsychiatry. 2022;55(1):40–7. DOI: https://doi.org/10.1055/a-1492-3293 56. Uvais NA. The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia. Prim Care Companion CNS Disord. 2020;22(3):20com02635. DOI: https://doi.org/10.4088/PCC.20com02635 57. Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–70. DOI: https://doi.org/10.1016/S2215-0366(14)00122-9 58. Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50. DOI: https://doi.org/10.1002/wps.20069 59. Pillinger T, D'Ambrosio E, McCutcheon R, Howes OD. Correction to: Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):928. DOI: https://doi.org/10.1038/s41380-018-0275-2 60. Almutairi MM, Sivandzade F, Albekairi TH, et al. Neuroinflammation and Its Impact on the Pathogenesis of COVID-19. Front Med (Lausanne). 2021;8:745789. DOI: https://doi.org/10.3389/fmed.2021.745789 61. Steardo LJr, Steardo L, Scuderi C. Astrocytes and the Psychiatric Sequelae of COVID-19: What We Learned from the Pandemic. Neurochem Res. 2023;48:1015–25. DOI: https://doi.org/10.1007/s11064-022-03709-7 62. Stefano GB, Büttiker P, Weissenberger S, et al. Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19. Curr Neuropharmacol. 2022;20(6):1229–40. DOI: https://doi.org/10.2174/1570159X20666211223130228 63. Pomilio AB, Vitale AA, Lazarowski AJ. COVID-19 and Alzheimer's Disease: Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved. Curr Med Chem. 2023;30(35):3993–4031. DOI: https://doi.org/10.2174/0929867329666221003101548 64. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758–63. DOI: https://doi.org/10.1038/s41586-022-05542-y 65. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168–75. DOI: https://doi.org/10.1038/s41593-020-00758-5 66. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268(9):3059–71. DOI: https://doi.org/10.1007/s00415-021-10406-y 67. Rai SN, Tiwari N, Singh P, et al. Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease. Oxid Med Cell Longev. 2022;2022:3012778. DOI: https://doi.org/10.1155/2022/3012778 68. Xia J, Chen S, Li Y, et al. Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis. Front Immunol. 2022;13:798538. DOI: https://doi.org/10.3389/fimmu.2022.798538 69. Liu N, Tan JS, Liu L, et al. Genetic Predisposition Between COVID-19 and Four Mental Illnesses: A Bidirectional, Two-Sample Mendelian Randomization Study. Front Psychiatry. 2021;12:746276. DOI: https://doi.org/10.3389/fpsyt.2021.746276 70. Chen W, Zeng Y, Suo C, et al. Genetic predispositions to psychiatric disorders and the risk of COVID-19. BMC Med. 2022;20(1):314. DOI: https://doi.org/10.1186/s12916-022-02520-z 71. Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 2020;134(23):3137–58. DOI: https://doi.org/10.1042/CS20201268 72. Nadalin S, Jakovac H, Peitl V, et al. Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID 19 (Review). Mol Med Rep. 2021;24(2):611. DOI: https://doi.org/10.3892/mmr.2021.12250 73. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–60. DOI: https://doi.org/10.1080/22221751.2020.1746200 74. Wincewicz D, Braszko JJ. Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders. Pharmacopsychiatry. 2017;50(6):233–47. DOI: https://doi.org/10.1055/s-0043-112345 75. Ren AL, Digby RJ, Needham EJ. Neurological update: COVID-19. J Neurol. 2021;268(11):4379–87. DOI: https://doi.org/10.1007/s00415-021-10581-y
Article Metrics
Metrics powered by PLOS ALM